{"product_id":"dbvt-ansoff-analysis","title":"(DBVT) DBV Technologies S.A. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis DBV Technologies S.A. Ansoff Matrix Analysis maps the company’s growth options—market penetration, market development, product development, and diversification—so you can quickly assess strategic paths for research, investing, or planning. The page already contains a real preview\/sample of the analysis showing style and substance; purchase the full version to download the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViaskin Peanut 4 to 11 core\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies’ Viaskin Peanut should keep market penetration focused on peanut allergy in children aged 4 to 11, where the company already has its clearest clinical proof. The Phase III PEPITES study enrolled 356 children in this age band, giving DBV its strongest evidence base for the core pediatric segment. Staying on the same indication and age group should support faster uptake and lower commercial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III peanut-allergy evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A. has already completed Phase III studies for Viaskin Peanut, including PEPITES and EPITOPE, so the main market-penetration lever is evidence, not new market creation. The goal is to turn late-stage data into stronger clinician and payer acceptance in the existing peanut-allergy space. With peanut allergy affecting about 2% of U.S. children, better proof on efficacy and safety can drive uptake in this current treatment market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpicutaneous delivery differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies’ market penetration rests on epicutaneous immunotherapy, which delivers allergen through the skin and keeps the Company distinct from oral and sublingual rivals in peanut allergy. Peanut allergy affects about 1% to 2% of children in many developed markets, so clear positioning matters for uptake. If the DBV Technologies brand stays tied to this delivery mode, it can defend its niche and avoid being seen as just another desensitization option.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLead-asset concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDBV Technologies S.A. is highly concentrated on Viaskin Peanut, its flagship asset for peanut allergy, so market penetration depends on pushing one program harder rather than spreading spend thin. That focus fits the current pipeline mix: the lead asset is the main near-term value driver, while the rest of the portfolio is still earlier stage and less ready to support revenue.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, this is the cleanest way to build share in the current market because a single approved or late-stage product can scale faster than a broad pipeline. The risk is concentration, but the payoff is clearer: more clinical, regulatory, and commercial effort goes into the one asset most likely to move DBV from R\u0026amp;D spend toward sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eViaskin Peanut drives near-term value.\u003c\/li\u003e\n\u003cli\u003eEarlier-stage assets add limited share today.\u003c\/li\u003e\n\u003cli\u003eFocused spend supports faster market entry.\u003c\/li\u003e\n\u003cli\u003eConcentration raises execution risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePeanut-allergy market depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDBV Technologies S.A. is still built around one target: peanut allergy. That fits a clinical-stage model, because peanut allergy affects about 2% of children and 0.5% of adults, so the company can push deeper in a defined market before widening its scope.\u003c\/p\u003e\n\u003cp\u003eIts lead program, Viaskin Peanut, has been tested in children as young as 1 to 3 years old, showing the commercial aim is share gain inside the same disease area, not fast category spread.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-allergy focus: peanut\u003c\/li\u003e\n\u003cli\u003eDeepen share before expansion\u003c\/li\u003e\n\u003cli\u003eFits clinical-stage logic\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViaskin Peanut Targets a Clear Existing Peanut-Allergy Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A. market penetration is tightly tied to Viaskin Peanut in the same peanut-allergy market, not a new segment. The clearest base is children aged 4 to 11, where PEPITES enrolled 356 patients, and peanut allergy still affects about 2% of U.S. children, so deeper clinician and payer acceptance can lift share inside an existing need.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead asset\u003c\/td\u003e\n\u003ctd\u003eViaskin Peanut\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore age group\u003c\/td\u003e\n\u003ctd\u003eChildren 4 to 11\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePEPITES sample\u003c\/td\u003e\n\u003ctd\u003e356 children\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. child prevalence\u003c\/td\u003e\n\u003ctd\u003eAbout 2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing DBV Technologies S.A.’s growth strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick, visual Ansoff Matrix for DBV Technologies S.A. to clarify growth options and simplify strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, credible sources that let stakeholders quickly verify DBV Technologies' Ansoff Matrix growth assumptions and speed due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdolescent peanut-allergy expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A. can widen Viaskin Peanut beyond its 4 to 11 core by serving adolescents, a larger peanut-allergy group that often keeps symptoms into the teen years. Peanut allergy affects about 2% of U.S. children, so extending one patch into the 12 to 17 segment can lift the addressable market without a new product. That makes this a classic market-development move.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult peanut-allergy expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eViaskin Peanut has also been studied in adults, so DBV Technologies S.A. can extend the same product into a new segment without changing the core platform. Adults are a separate market from the pediatric base, and peanut allergy still affects about 1.8% of U.S. adults, or roughly 4.6 million people. That makes this a clear market-development move with new revenue upside from the same asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader age-cohort reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A.'s Viaskin Peanut is not tied to one age band: it has been studied in children, adolescents, and adults, widening the addressable market beyond the first pediatric target. PEPITES enrolled 356 children aged 4 to 11, while EPITOPE added 146 toddlers aged 1 to 3, showing reach across early life stages. That broader age-cohort base supports a larger, more durable adoption path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAge-based peanut-allergy expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDBV Technologies S.A. can widen its peanut-allergy market from one pediatric age band to several by reusing the same Viaskin Peanut platform. Its Phase III EPITOPE study was designed in 362 children aged 1 to 3 years, so the program already supports age-based expansion into adjacent cohorts without rebuilding the product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame product, more age brackets\u003c\/li\u003e\n\u003cli\u003eEPITOPE: 362 children, ages 1 to 3\u003c\/li\u003e\n\u003cli\u003eNew cohorts can lift patient reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-segment peanut-allergy access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDBV Technologies S.A. can grow by age segment, not by changing peanut allergy itself: Viaskin Peanut is built for the same disease, but first for younger patients. The company's core asset already targets children 1-7 in recent clinical work, so moving into older pediatric groups is a clean market-development step. That matters because peanut allergy persists into adolescence and adulthood, keeping the addressable pool broad.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame disease, new age bands\u003c\/li\u003e\n\u003cli\u003eCore asset stays unchanged\u003c\/li\u003e\n\u003cli\u003eBroader addressable pool\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDBV Expands Viaskin Peanut to New Age Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A. uses Viaskin Peanut to reach new age groups, not a new disease, which fits market development. Peanut allergy affects about 2% of U.S. children and about 1.8% of U.S. adults, or roughly 4.6 million people, so moving from ages 1 to 11 into teens and adults can expand sales from the same platform.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. children with peanut allergy\u003c\/td\u003e\n\u003ctd\u003eAbout 2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. adults with peanut allergy\u003c\/td\u003e\n\u003ctd\u003eAbout 1.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult patient pool\u003c\/td\u003e\n\u003ctd\u003eAbout 4.6 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViaskin Peanut strategy\u003c\/td\u003e\n\u003ctd\u003eNew age segments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eDBV Technologies S.A. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViaskin Milk Phase I\/II\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A. is developing Viaskin Milk for IgE-mediated cow’s milk protein allergy, and it is in Phase I\/II trials. This is a new product for an allergy-focused company, so it fits the product development step in the Ansoff Matrix. The program targets a large unmet need in food allergy, where cow’s milk is one of the most common pediatric triggers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViaskin Egg pre-clinical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eViaskin Egg is in pre-clinical work for hen’s egg allergy, so DBV Technologies S.A. is extending its food-allergy pipeline from 2 targets, peanut and milk, to 3. That is a clear product-development move in the Ansoff Matrix, because it uses the same Viaskin skin-delivery platform to add a new allergy indication inside the core franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMAG1C patch test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies and Nestlé Health Science are developing MAG1C, a user-friendly atopy patch test for non-IgE mediated cow’s milk protein allergy, which is a new diagnostic product for DBV Technologies. Non-IgE cow’s milk protein allergy affects about 2% to 5% of infants, so the addressable niche is small but clinically clear. This fits the Product Development cell in Ansoff Matrix by extending DBV Technologies into diagnostics with Nestlé Health Science’s reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInfant toddler diagnosis tool\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMAG1C gives DBV Technologies a product step into pediatric allergy diagnostics, aimed at infants and toddlers, so the company is no longer tied only to treatment-led assets. That matters because DBV had 0 marketed products in 2025, making a diagnostic entry a broader revenue path if clinical validation converts. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInfants and toddlers are the core target\u003c\/li\u003e\n\u003cli\u003eAdds diagnostics to DBV’s mix\u003c\/li\u003e\n\u003cli\u003eCould widen pediatric allergy reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEpicutaneous platform extensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDBV Technologies S.A. is using one epicutaneous core across therapy and diagnosis, so Product Development stays focused on a single platform instead of scattered bets. The best proof is Viaskin Peanut, which advanced in the EPITOPE study with 356 young children aged 1 to 3, showing how the same patch tech can keep feeding the pipeline.\u003c\/p\u003e\n\u003cp\u003eThis reuse matters because it lowers development friction and keeps know-how inside one system. DBV can extend the same skin-delivery science into new treatment and diagnostic uses, which makes the roadmap steadier and more capital efficient than starting from scratch each time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne core epicutaneous platform\u003c\/li\u003e\n\u003cli\u003eReuse across treatment and diagnosis\u003c\/li\u003e\n\u003cli\u003eEPITOPE: 356 children enrolled\u003c\/li\u003e\n\u003cli\u003eSteadier pipeline, lower platform risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDBV Expands Viaskin Into Milk, Egg, and Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A. is using Product Development by extending its Viaskin platform into new allergy uses, led by Viaskin Milk and Viaskin Egg. This keeps the company inside one epicutaneous system while adding new targets beyond peanut. MAG1C also adds a diagnostic path with Nestlé Health Science.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eViaskin Milk\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II\u003c\/td\u003e\n\u003ctd\u003eNew therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViaskin Egg\u003c\/td\u003e\n\u003ctd\u003ePre-clinical\u003c\/td\u003e\n\u003ctd\u003eNew therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAG1C\u003c\/td\u003e\n\u003ctd\u003eDevelopment\u003c\/td\u003e\n\u003ctd\u003eNew diagnosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBordetella pertussis booster vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A.'s Bordetella pertussis booster vaccine is clear diversification: it shifts the Company from food allergy into infectious disease, with a new product for a new market. Pertussis still drives major unmet need, with WHO-linked estimates near 24 million cases and about 160,000 deaths a year, mostly in young children. That gives DBV a much broader addressable market than its allergy-focused base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRespiratory syncytial virus vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A. moving into an respiratory syncytial virus vaccine would be diversification because RSV is outside its allergy core and opens a new product-market path. RSV drives about 33 million lower respiratory infections and over 100,000 child deaths each year worldwide, so the addressable need is large. If DBV can build early-stage data in this field, it broadens growth beyond its existing pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrohn’s disease therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A.'s move into Crohn’s disease therapies would sit in the diversification quadrant: a new product for a new market. Crohn’s is a separate immunology market from peanut, milk, and egg allergy, with about 780,000 Americans affected and millions more worldwide. That makes the opportunity bigger, but also riskier, because DBV must build new clinical, regulatory, and commercial capabilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCeliac disease therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDBV Technologies S.A. is using diversification to move beyond allergy care into celiac disease therapies, a new therapeutic market for the company. Celiac disease affects about 1% of people worldwide, so even early research could open a much larger addressable market than its current allergy focus.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew market: celiac disease\u003c\/li\u003e\n\u003cli\u003eEarlier-stage R\u0026amp;D only\u003c\/li\u003e\n\u003cli\u003eBroadens beyond allergies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis is a strategic spread bet, but it still carries high development risk because the program is not yet commercial. The upside is clear: a 1% global disease pool gives DBV a wider growth lane than a single-allergy platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eType I diabetes therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDBV Technologies S.A. is extending diversification into type I diabetes, a new disease area and patient pool beyond allergy. The global type 1 diabetes market was about 9.1 million people in 2025, and DBV Technologies S.A. reported 2025 cash and cash equivalents of about €37 million, giving it room to test this wider pipeline. This move reduces single-therapy dependence but stays high risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew market: type I diabetes\u003c\/li\u003e\n\u003cli\u003eBroader pipeline beyond allergy\u003c\/li\u003e\n\u003cli\u003e2025 market: 9.1 million people\u003c\/li\u003e\n\u003cli\u003e2025 cash: about €37 million\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDBV’s Big Bet: Diversifying Beyond Food Allergy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDBV Technologies S.A.’s diversification is a move from food allergy into new disease areas like pertussis, RSV, Crohn’s, celiac disease, and type I diabetes. That expands the Company beyond a single-therapy base, but each bet needs new clinical and regulatory work. In 2025, type I diabetes covered about 9.1 million people, while DBV Technologies S.A. had about €37 million cash and cash equivalents.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eType I diabetes\u003c\/td\u003e\n\u003ctd\u003e9.1 million people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e€37 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234365317385,"sku":"dbvt-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/dbvt-ansoff-matrix.webp?v=1785716581","url":"https:\/\/dcfanalyst.com\/products\/dbvt-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}